Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
1,971
Views
2
CrossRef citations to date
0
Altmetric
Original Research

No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19

Adriana Petrazzuoloa Equipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France;c Faculty of Medicine Kremlin Bicêtre, Université Paris Saclay, Paris, France
,
Julie Le Naoura Equipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France;c Faculty of Medicine Kremlin Bicêtre, Université Paris Saclay, Paris, FranceORCID Iconhttps://orcid.org/0000-0002-3749-2171
ORCID Icon,
Erika Vacchellia Equipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, FranceORCID Iconhttps://orcid.org/0000-0001-8010-0594
ORCID Icon,
Pascale Gaussemd Hematology Department and Biosurgical Research Lab, (Carpentier Foundation) Assistance Publique Hôpitaux De Paris-Centre Université De Paris (APHP-CUP), Paris, France;e Innovative Therapies in Haemostasis, INSERM, Université De Paris, Paris, France
,
Syrine Ellouzef Biological Hematology Department, Assistance Publique-Hôpitaux De Paris. Centre-Université De Paris, Paris, France
,
Georges Jourdie Innovative Therapies in Haemostasis, INSERM, Université De Paris, Paris, France;f Biological Hematology Department, Assistance Publique-Hôpitaux De Paris. Centre-Université De Paris, Paris, France
,
Eric Solaryc Faculty of Medicine Kremlin Bicêtre, Université Paris Saclay, Paris, France;g INSERM U1287, Gustave Roussy Cancer Center, Villejuif, France;h Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France
,
Michaela Fontenayf Biological Hematology Department, Assistance Publique-Hôpitaux De Paris. Centre-Université De Paris, Paris, France;i Institut Cochin, CNRS UMR8104, INSERM U1016, Université De Paris, Paris, France
,
David M. Smadjad Hematology Department and Biosurgical Research Lab, (Carpentier Foundation) Assistance Publique Hôpitaux De Paris-Centre Université De Paris (APHP-CUP), Paris, France;e Innovative Therapies in Haemostasis, INSERM, Université De Paris, Paris, France
&
Guido Kroemera Equipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France;j Institut Universitaire De France, Paris, France;k AP-HP, Hôpital Européen Georges Pompidou, Paris, France;l Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China;m Karolinska Institute, Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9334-4405
ORCID Icon show all
Article: 1857112 | Received 05 Nov 2020, Accepted 25 Nov 2020, Published online: 08 Dec 2020

Figures & data

Table 1. Allelic frequencies of FPR1 SNPs and characteristics of patient population from Hôpital Cochin and Hôpital Européen George Pompidou

Figure 1. Severity and survival of patients diagnosed with COVID19 bearing at least one copy of the variant allele of rs867228 and rs5030880 SNPs. Proportion of patients diagnosed with critical, severe, moderate and mild COVID19 disease from Hôpital Cochin (a) and Hôpital Européen George Pompidou (HEGP) (c). Patients’ survival is shown as proportion of alive and dead subjects from Hôpital Cochin (b) and HEGP (d). Severity (e) and survival (f) of cumulative data from the two above mentioned hospitals. Statistical significance was calculated using the chi-squared test

Figure 1. Severity and survival of patients diagnosed with COVID19 bearing at least one copy of the variant allele of rs867228 and rs5030880 SNPs. Proportion of patients diagnosed with critical, severe, moderate and mild COVID19 disease from Hôpital Cochin (a) and Hôpital Européen George Pompidou (HEGP) (c). Patients’ survival is shown as proportion of alive and dead subjects from Hôpital Cochin (b) and HEGP (d). Severity (e) and survival (f) of cumulative data from the two above mentioned hospitals. Statistical significance was calculated using the chi-squared test

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.